As Shareholder Vote Looms, Genesis Provides New Details on ssRNAi Subsidiary
October 15, 2009
As Shareholder Vote Looms, Genesis Provides New Details on ssRNAi Subsidiary
According to Genesis, the primary investor in the subsidiary is Japan's MediBic Group, which is primarily a pharmacogenomics firm but has made investments in RNAi drug shop Intradigm.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.